Semin Respir Crit Care Med 2008; 29(3): 291-301
DOI: 10.1055/s-2008-1076749
© Thieme Medical Publishers

Targeted Therapy in Advanced Non-Small-Cell Lung Cancer

Scott Gettinger1
  • 1Section of Medical Oncology, Department of Internal Medicine, Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut
Further Information

Publication History

Publication Date:
02 June 2008 (online)

ABSTRACT

Molecularly targeted therapies have recently expanded the options available for patients with advanced non-small-cell lung cancer (NSCLC). Two cancer cell pathways in particular have been exploited, the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathway. The former has emerged as a key regulator of cancer cell proliferation and invasion, and several EGFR inhibitors have been developed. Erlotinib, a small-molecule inhibitor of the EGFR intracellular tyrosine kinase, has been found to improve survival compared with placebo in previously treated patients with advanced NSCLC and is Food and Drug Administration (FDA)-approved in this setting. Clinical and molecular predictors of response to erlotinib, such as a history of never smoking and EGFR gene mutation or amplification, are presently being evaluated to select patients for earlier therapy with erlotinib. Additional EGFR inhibitors are also being examined in randomized trials. The VEGF pathway, a key mediator of angiogenesis, has become an attractive target in multiple malignancies, including lung cancer. Bevacizumab, a monoclonal antibody to VEGF, received FDA approval for use in advanced non-squamous-cell NSCLC in 2006 after a phase III trial reported a significant survival advantage when bevacizumab was added to standard first-line chemotherapy. Small-molecule inhibitors of the VEGF receptor tyrosine kinase, such as sunitinib and sorafenib, have also shown promise in phase II trials and are being further investigated in phase III studies. Because preclinical data suggest a synergistic effect when VEGF and EGFR inhibitors are combined, the concurrent use of erlotinib and bevacizumab has additionally been evaluated in a phase II trial, with encouraging early results suggesting at least equivalent activity to standard salvage chemotherapy, with less toxicity. Several other novel agents are being examined, including inhibitors of histone deacteylases and the 26S proteosome. Research efforts are currently focusing on tailoring such therapies according to predictive clinical and molecular markers.

REFERENCES

  • 1 Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun M J. Cancer statistics, 2007.  CA Cancer J Clin. 2007;  57 43-66
  • 2 Olayioye M A, Neve R M, Lane H A, Hynes N E. The ErbB signaling network: receptor heterodimerization in development and cancer.  EMBO J. 2000;  19 3159-3167
  • 3 Isobe T, Herbst R S, Onn A. Current management of advanced non-small cell lung cancer: targeted therapy.  Semin Oncol. 2005;  32 315-328
  • 4 Kris M G, Natale R B, Herbst R S et al.. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.  JAMA. 2003;  290 2149-2158
  • 5 Fukuoka M, Yano S, Giaccone G et al.. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial).  , [corrected] J Clin Oncol. 2003;  21 2237-2246
  • 6 Thatcher N, Chang A, Parikh P et al.. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer).  Lancet. 2005;  366 1527-1537
  • 7 Shepherd F A, Rodrigues Pereira J, Ciuleanu T et al.. Erlotinib in previously treated non-small-cell lung cancer.  N Engl J Med. 2005;  353 123-132
  • 8 Lee D H, Han J Y, Yu S Y et al.. The role of gefitinib treatment for Korean never smokers with advanced or metastatic adenocarcinoma of the lung: a prospective study.  J Thorac Oncol. 2006;  1 965-971
  • 9 Lynch T J, Bell D W, Sordella R et al.. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.  N Engl J Med. 2004;  350 2129-2139
  • 10 Paez J G, Janne P A, Lee J C et al.. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.  Science. 2004;  304 1497-1500
  • 11 Asahina H, Yamazaki K, Kinoshita I et al.. A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations.  Br J Cancer. 2006;  95 998-1004
  • 12 Sutani A, Nagai Y, Udagawa K et al.. Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp.  Br J Cancer. 2006;  95 1483-1489
  • 13 Inoue A, Suzuki T, Fukuhara T et al.. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations.  J Clin Oncol. 2006;  24 3340-3346
  • 14 Sunaga N, Tomizawa Y, Yanagitani N et al.. Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy.  Lung Cancer. 2007;  56 383-389
  • 15 Paz-Ares L, Sanchez J M, Garcia-Velasco A et al.. A prospective phase II trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients (p) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR). ASCO Meeting Abstracts. June 20, 2006 24(18 Suppl): 7020
  • 16 Shepherd F A, Tsao M-S. Unraveling the mystery of prognostic and predictive factors in epidermal growth factor receptor therapy.  J Clin Oncol. 2006;  24 1219-1220
  • 17 Tsao M S, Sakurada A, Cutz J C et al.. Erlotinib in lung cancer: molecular and clinical predictors of outcome.  N Engl J Med. 2005;  353 133-144
  • 18 Hirsch F R, Varella-Garcia M, Bunn Jr P A et al.. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer.  J Clin Oncol. 2006;  24 5034-5042
  • 19 Pao W, Wang T Y, Riely G J et al.. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib.  PLoS Med. 2005;  2 e17
  • 20 Wacker B, Nagrani T, Weinberg J, Witt K, Clark G, Cagnoni P J. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies.  Clin Cancer Res. 2007;  13 3913-3921
  • 21 Herbst R S, Prager D, Hermann R et al.. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.  J Clin Oncol. 2005;  23 5892-5899
  • 22 Gatzemeier U, Pluzanska A, Szczesna A et al.. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial.  J Clin Oncol. 2007;  25 1545-1552
  • 23 Herbst R S, Giaccone G, Schiller J H et al.. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial–INTACT 2.  J Clin Oncol. 2004;  22 785-794
  • 24 Giaccone G, Herbst R S, Manegold C et al.. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial–INTACT 1.  J Clin Oncol. 2004;  22 777-784
  • 25 Herbst R S, Chansky K, Kelly K et al.. A phase II randomized selection trial evaluating concurrent chemotherapy plus cetuximab or chemotherapy followed by cetuximab in patients with advanced non-small cell lung cancer (NSCLC): final report of SWOG 0342. ASCO Meeting Abstracts June 20, 2007 25(18 Suppl): 7545
  • 26 Kim E S, Mauer A M, Tran H T et al.. A phase II study of cetuximab, an epidermal growth factor receptor (EGFR) blocking antibody, in combination with docetaxel in chemotherapy refractory/resistant patients with advanced non-small cell lung cancer: final report. ASCO Meeting Abstracts 2003 22: 2581
  • 27 Rosell R, Daniel C, Ramlau R et al.. Randomized phase II study of cetuximab in combination with cisplatin (C) and vinorelbine (V) vs. CV alone in the first-line treatment of patients (pts) with epidermal growth factor receptor (EGFR)-expressing advanced non-small-cell lung cancer (NSCLC). ASCO Meeting Abstracts July 15, 2004 22(14 Suppl): 7012
  • 28 Butts C A, Bodkin D, Middleman E L et al.. Gemcitabine/platinum alone or in combination with cetuximab as first-line treatment for advanced non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts June 20, 2007 25(18 Suppl): 7539
  • 29 Jalal S I, Waterhouse D, Edelman M et al.. Pemetrexed plus cetuximab in patients (pts) with recurrent non-small cell lung cancer (NSCLC): A phase I–IIa dose-ranging study from the Hoosier Oncology Group. ASCO Meeting Abstracts June 20, 2007 25(18_suppl): 7698
  • 30 Bonner J A, Harari P M, Giralt J et al.. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.  N Engl J Med. 2006;  354 567-578
  • 31 Blumenschein Jr G, Moughan J, Curran W et al.. A phase II study of cetuximab (C225) in combination with chemoradiation (CRT) in patients (pts) with stage III A/B non-small cell lung cancer (NSCLC): an interim report of the RTOG 0324 trial. ASCO Meeting Abstracts June 20, 2007 25(18 Suppl): 7531
  • 32 Socinski M A. Antibodies to the Epidermal Growth Factor Receptor in Non Small Cell Lung Cancer: Current Status of Matuzumab and Panitumumab.  Clin Cancer Res. 2007;  13 4597s-4601
  • 33 Huang S, Armstrong E A, Benavente S, Chinnaiyan P, Harari P M. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.  Cancer Res. 2004;  64 5355-5362
  • 34 Matar P, Rojo F, Cassia R et al.. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.  Clin Cancer Res. 2004;  10 6487-6501
  • 35 Okabe T, Okamoto I, Tamura K et al.. Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification.  Cancer Res. 2007;  67 2046-2053
  • 36 Naret C L, Ramalingam S, Beattie L et al.. Total blockade of the epidermal growth factor receptor with the combination of cetuximab and gefitinib: a phase I study for patients with recurrent non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts June 20, 2006 24(18 Suppl): 17045
  • 37 Baselga J, Schoffski P, Rojo F et al.. A phase I pharmacokinetic (PK) and molecular pharmacodynamic (PD) study of the combination of two anti-EGFR therapies, the monoclonal antibody (MAb) cetuximab (C) and the tyrosine kinase inhibitor (TKI) gefitinib (G), in patients (pts) with advanced colorectal (CRC), head and neck (HNC) and non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts June 20, 2006 24(18 Suppl): 3006
  • 38 Preston G G, Calvo E, Papadopoulos K et al.. Multi-targeted inhibition of the epidermal growth factor (EGFR) and vascular endothelial growth factor receptor (VEGFR) pathways: a phase I study of cetuximab (C), erlotinib (E), and bevacizumab (B) in patients with solid tumors. ASCO Meeting Abstracts June 20, 2006 24(18 Suppl): 3005
  • 39 Bergers G, Benjamin L E. Tumorigenesis and the angiogenic switch.  Nat Rev Cancer. 2003;  3 401-410
  • 40 Bremnes R M, Camps C, Sirera R. Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood.  Lung Cancer. 2006;  51 143-158
  • 41 Jain R K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy.  Science. 2005;  307 58-62
  • 42 Johnson D H, Fehrenbacher L, Novotny W F et al.. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer.  J Clin Oncol. 2004;  22 2184-2191
  • 43 Hurwitz H, Fehrenbacher L, Novotny W et al.. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.  N Engl J Med. 2004;  350 2335-2342
  • 44 Ramalingam S S, Dahlberg S E, Langer C J et al.. Outcomes for elderly advanced stage non-small cell lung cancer (NSCLC) patients (pts) treated with bevacizumab (B) in combination with carboplatin (C) and paclitaxel (P): analysis of Eastern Cooperative Oncology Group (ECOG) 4599 study. ASCO Meeting Abstracts June 20, 2007 25(18 Suppl): 7535
  • 45 Ferrara N. VEGF and the quest for tumour angiogenesis factors.  Nat Rev Cancer. 2002;  2 795-803
  • 46 Gatzemeier U, Blumenschein G, Fosella F et al.. Phase II trial of single-agent sorafenib in patients with advanced non-small cell lung carcinoma. ASCO Meeting Abstracts June 20, 2006 24(18 Suppl): 7002
  • 47 Schiller J H, Flaherty K T, Redlinger M et al.. Sorafenib combined with carboplatin/paclitaxel for advanced non-small cell lung cancer: a phase I subset analysis. ASCO Meeting Abstracts June 20, 2006 24(18 Suppl): 7194
  • 48 Socinski M A, Novello S, Sanchez J M et al.. Efficacy and safety of sunitinib in previously treated, advanced non-small cell lung cancer (NSCLC): preliminary results of a multicenter phase II trial. ASCO Meeting Abstracts June 20, 2006 24(18 Suppl): 7001
  • 49 Brahmer J R, Govindan R, Novello S et al.. Efficacy and safety of continuous daily sunitinib dosing in previously treated advanced non-small cell lung cancer (NSCLC): results from a phase II study. ASCO Meeting Abstracts June 20, 2007 25(18 Suppl): 7542
  • 50 Natale R B, Bodkin D, Govindan R et al.. ZD6474 versus gefitinib in patients with advanced NSCLC: final results from a two-part, double-blind, randomized phase II trial. ASCO Meeting Abstracts June 20, 2006 24(18 Suppl): 7000
  • 51 Heymach J V, Johnson B E, Prager D et al.. A phase II trial of ZD6474 plus docetaxel in patients with previously treated NSCLC: follow-up results. ASCO Meeting Abstracts June 20, 2006 24(18 Suppl): 7016
  • 52 Petit A M, Rak J, Hung M C et al.. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.  Am J Pathol. 1997;  151 1523-1530
  • 53 Hirata A, Ogawa S, Kometani T et al.. ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase.  Cancer Res. 2002;  62 2554-2560
  • 54 Kim S J, Uehara H, Karashima T, Shepherd D L, Killion J J, Fidler I J. Blockade of epidermal growth factor receptor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice.  Clin Cancer Res. 2003;  9 1200-1210
  • 55 Ciardiello F, Caputo R, Damiano V et al.. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase.  Clin Cancer Res. 2003;  9 1546-1556
  • 56 Guy S P, Ashton S, Hughes G et al.. Gefitinib (Iressa, ZD1839) enhances the activity of the novel vascular-targeting agent ZD6126 in human colorectal cancer and non-small cell lung cancer (NSCLC) xenograft models [abstract B13].  Clin Cancer Res. 2003;  9(Suppl) 6142s
  • 57 Fehrenbacher L, O'Neill V, Belani C P et al.. A phase II, multicenter, randomized clinical trial to evaluate the efficacy and safety of bevacizumab in combination with either chemotherapy (docetaxel or pemetrexed) or erlotinib hydrochloride compared with chemotherapy alone for treatment of recurrent or refractory non-small cell lung cancer. ASCO Meeting Abstracts June 20, 2006 24(18 Suppl): 7062
  • 58 Davies A M, Lara Jr P N, Mack P C, Gandara D R. Incorporating bortezomib into the treatment of lung cancer.  Clin Cancer Res. 2007;  13(15 Pt 2) s4647-s4651
  • 59 Schenkein D P. Use of proteasome inhibition in the treatment of lung cancer.  Clin Lung Cancer. 2004;  6(Suppl 2) S89-S96
  • 60 Aghajanian C, Soignet S, Dizon D S et al.. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies.  Clin Cancer Res. 2002;  8 2505-2511
  • 61 Stevenson J P, Nho C W, Johnson S W et al.. Effects of bortezomib (PS-341) on NF-{kappa}B activation in peripheral blood mononuclear cells (PBMCs) of advanced non-small lung cancer (NSCLC) patients: a phase II/pharmacodynamic trial. ASCO Meeting Abstracts July 15, 2004 22(14 Suppl): 7145
  • 62 Fanucchi M P, Fossella F V, Belt R et al.. Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer.  J Clin Oncol. 2006;  24 5025-5033
  • 63 Davies A M, McCoy J, Lara Jr P N et al.. Bortezomib + gemcitabine (Gem)/carboplatin (Carbo) results in encouraging survival in advanced non-small cell lung cancer (NSCLC): results of a phase II Southwest Oncology Group (SWOG) trial (S0339). ASCO Meeting Abstracts June 20, 2006 24(18 Suppl): 7017
  • 64 Marks P A, Richon V M, Rifkind R A. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells.  J Natl Cancer Inst. 2000;  92 1210-1216
  • 65 Kim M S, Blake M, Baek J H, Kohlhagen G, Pommier Y, Carrier F. Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA.  Cancer Res. 2003;  63 7291-7300
  • 66 Aparicio A. The potential of histone deacetylase inhibitors in lung cancer.  Clin Lung Cancer. 2006;  7 309-312
  • 67 Ramalingam S S, Parise R A, Ramananthan R K et al.. Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies.  Clin Cancer Res. 2007;  13 3605-3610
  • 68 Schiller J H, Larson T, Ou S I et al.. Efficacy and safety of axitinib (AG-013736; AG) in patients (pts) with advanced non-small cell lung cancer (NSCLC): a phase II trial. ASCO Meeting Abstracts June 20, 2007 25(18 Suppl): 7507
  • 69 McKeage M, Investigators A SSG. Phase Ib/II study of DMXAA combined with carboplatin and paclitaxel in non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts June 20, 2006 24(18 Suppl): 7102
  • 70 Bepler G, Oh Y, Burris H, Cleverly A, Lahn M, Herbst R S. A phase II study of enzastaurin as second- or third-line treatment of non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts June 20, 2007 25(18 Suppl): 7543
  • 71 Kris M G, Riely G J, Azzoli C G et al.. Combined inhibition of mTOR and EGFR with everolimus (RAD001) and gefitinib in patients with non-small cell lung cancer who have smoked cigarettes: a phase II trial. ASCO Meeting Abstracts June 20, 2007 25(18 Suppl): 7575
  • 72 Karp D D, Paz-Ares L G, Blakely L J et al.. Efficacy of the anti-insulin like growth factor I receptor (IGF-IR) antibody CP-751871 in combination with paclitaxel and carboplatin as first-line treatment for advanced non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts June 20, 2007 25(18 Suppl): 7506
  • 73 LoRusso P, Hong D, Heath E et al.. First-in-human study of AMG 655, a pro-apoptotic TRAIL receptor-2 agonist, in adult patients with advanced solid tumors. ASCO Meeting Abstracts June 20, 2007 25(18 Suppl): 3534
  • 74 Papadimitrakopoulou V, Blumenschein G, Fossella F et al.. O-287 Phase 2 study of TLK286 (GST P1–1 activated glutathione analog) administered weekly in patients with platinum refractory of resistant non-small cell lung cancer (NSCLC).  , Abstract of the 10th World Conference on Lung Cancer Lung Cancer. 2003;  41(Suppl 2) S83-S84
  • 75 Sangha R, Butts C. L-BLP25: a peptide vaccine strategy in non small cell lung cancer.  Clin Cancer Res. 2007;  13(15 Pt 2) s4652-s4654
  • 76 Vansteenkiste J, Zielinski M, Linder A et al.. Final results of a multi-center, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts June 20, 2007 25(18 Suppl): 7554
  • 77 Nemunaitis J, Dillman R O, Schwarzenberger P O et al.. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer.  J Clin Oncol. 2006;  24 4721-4730

Scott GettingerM.D. 

Section of Medical Oncology, Department of Internal Medicine, Yale Cancer Center, Yale University School of Medicine

333 Cedar St., FMP 130, New Haven, CT 06520

Email: scott.gettinger@yale.edu

    >